Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivanisiran for Dry Eye in Sjögren's Syndrome
NCT04819269Phase 3Completed
- Sponsor
- Sylentis
- Start
- May 2021
- Primary completion
- Dec 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 2
01
Overview
A Phase 3 trial of tivanisiran in dry eye disease (DED), sponsored by Sylentis. Started May 2021; status: completed.
02
Drugs
tivanisiran
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT04819269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04819269.